470 Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer
S. Glück, C. Lobo, G. Lopes, A. Castrellon, J. Hurley, I. Reis, S. Richman, O. Silva, J. Slingerland, C. WelshVolume:
8
Year:
2010
Language:
english
DOI:
10.1016/s1359-6349(10)70491-2
File:
PDF, 49 KB
english, 2010